Metformin and secukinumab for overweight patients with psoriasis
Treatments studied
Part of Hormones & metabolism, Skin clinical trials.
This study tests whether adding metformin (a diabetes medicine) to secukinumab (a biologic injection) works better for people with moderate-to-severe plaque psoriasis who are overweight or obese. It might help control psoriasis and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have had plaque psoriasis for at least 6 months, and it is moderate to severe (covers a lot of skin or is hard to control).
- You are overweight or obese (BMI of 25 or higher).
- You are not currently taking other psoriasis treatments like methotrexate or certain biologics (check with the study team).
- You do not have type 2 diabetes, active infections (like tuberculosis or hepatitis), or a history of cancer in the last 5 years.
- If you can become pregnant, you must use effective birth control during the study and for 15 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study looks at how well secukinumab works for psoriasis patients who also have a type of fatty liver disease called MASLD. It may help doctors understand if this treatment is a good option for people with both conditions.
This study looks at whether losing weight can improve the effectiveness of psoriasis treatments in people who are overweight or obese. If you have plaque psoriasis and are overweight, you may be able to join.
This trial tests whether adding tirzepatide (a weight-loss and diabetes drug) to ixekizumab (a psoriasis treatment) helps people with moderate-to-severe psoriasis who are overweight or have obesity. It is for those already taking ixekizumab for about 3 months.
This study tests a new topical cream for treating mild to moderate plaque psoriasis. It aims to see if the cream is safe and effective for reducing psoriasis symptoms.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.